1. Guariguata, L, Whiting, DR, Hambleton, I, et al. (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103, 137–149.
2. Sherwin, RS, Anderson, RM, Buse, JB, et al. (2003) The prevention or delay of type 2 diabetes. Diabetes Care 26, S62–S69.
3. Nathan, DM (1993) Long-term complications of diabetes mellitus. N Engl J Med 328, 1676–1685.
4. Backhed, F, Ding, H, Wang, T, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101, 15718–15723.
5. Rabot, S, Membrez, M, Bruneau, A, et al. (2010) Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J 24, 4948–4959.
6. Lindsay, KL, Kennelly, M, Culliton, M, et al. (2014) Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). Am J Clin Nutr 99, 1432–1439.
7. Ley, RE, Backhed, F, Turnbaugh, P, et al. (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102, 11070–11075.
8. Ley, RE, Turnbaugh, PJ, Klein, S, et al. (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023.
9. Yadav, H, Lee, J-H, Lloyd, J, et al. (2013) Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288, 25088–25097.
10. Ejtahed, HS, Mohtadi-Nia, J, Homayouni-Rad, A, et al. (2012) Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 28, 539–543.
11. Yadav, H, Jain, S & Sinha, PR (2008) Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. J Dairy Res 75, 189–195.
12. Hove, KD, Brons, C, Faerch, K, et al. (2015) Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. Eur J Endocrinol 172, 11–20.
13. Tajabadi-Ebrahimi, M, Sharifi, N, Farrokhian, A, et al. (2017) A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease. Exp Clin Endocrinol Diabetes 125, 21–27.
14. Moreno-Indias, I, Cardona, F, Tinahones, FJ, et al. (2014) Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol 5, 190.
15. Jumpertz, R, Le, DS, Turnbaugh, PJ, et al. (2011) Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 94, 58–65.
16. Turnbaugh, PJ, Backhed, F, Fulton, L, et al. (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–223.
17. Shavakhi, A, Minakari, M, Firouzian, H, et al. (2013) Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial. Int J Prev Med 4, 531–537.
18. Turnbaugh, PJ, Hamady, M, Yatsunenko, T, et al. (2009) A core gut microbiome in obese and lean twins. Nature 457, 480–484.
19. Turnbaugh, PJ, Ley, RE, Mahowald, MA, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1131.
20. Larsen, N, Vogensen, FK, van den Berg, FW, et al. (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5, e9085.
21. Wu, X, Ma, C, Han, L, et al. (2010) Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61, 69–78.
22. Qin, J, Li, Y, Cai, Z, et al. (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60.
23. Everard, A, Belzer, C, Geurts, L, et al. (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110, 9066–9071.
24. Shin, NR, Lee, JC, Lee, HY, et al. (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735.
25. Org, E, Parks, BW, Joo, JW, et al. (2015) Genetic and environmental control of host–gut microbiota interactions. Genome Res 25, 1558–1569.
26. Li, J, Lin, S, Vanhoutte, PM, et al. (2016)
Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe
mice. Circulation 133, 2434–2446.
27. Schneeberger, M, Everard, A, Gomez-Valades, AG, et al. (2015)
Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep 5, 16643.
28. Dao, MC, Everard, A, Aron-Wisnewsky, J, et al. (2016)
Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436.
29. Vrieze, A, Van Nood, E, Holleman, F, et al. (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916.e7.
30. Bäckhed, F, Manchester, JK, Semenkovich, CF, et al. (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 104, 979–984.
31. Cani, PD, Amar, J, Iglesias, MA, et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772.
32. Cani, PD, Bibiloni, R, Knauf, C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes 57, 1470–1481.
33. Wellen, KE, Fucho, R, Gregor, MF, et al. (2007) Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 129, 537–548.
34. Waki, H & Tontonoz, P (2007) STAMPing out inflammation. Cell 129, 451–452.
35. Bouter, KE, van Raalte, DH, Groen, AK, et al. (2017) Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. Gastroenterology 152, 1671–1678.
36. Araya, M, Morelli, L, Reid, G, et al. (2002) Guidelines for the evaluation of probiotics in food. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada, April 30 and May 1, 2002. http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
37. Homayoni Rad, A, Mehrabany, EV, Alipoor, B, et al. (2012) Do probiotics act more efficiently in foods than in supplements? Nutrition 28, 733–736.
38. Champagne, CP, Ross, RP, Saarela, M, et al. (2011) Recommendations for the viability assessment of probiotics as concentrated cultures and in food matrices. Int J Food Microbiol 149, 185–193.
39. Reid, G (2008) Probiotics and prebiotics – progress and challenges. Int Dairy J 18, 969–975.
40. Saraf, K, Shashikanth, M, Priy, T, et al. (2010) Probiotics – do they have a role in medicine and dentistry? JAPI 58, 488–492.
41. Bermudez-Brito, M, Plaza-Diaz, J, Munoz-Quezada, S, et al. (2012) Probiotic mechanisms of action. Ann Nutr Metab 61, 160–174.
42. Laitinen, K, Poussa, T & Isolauri, E (2009) Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr 101, 1679–1687.
43. Andreasen, AS, Larsen, N, Pedersen-Skovsgaard, T, et al. (2010) Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 104, 1831–1838.
44. Mohamadshahi, M, Veissi, M, Haidari, F, et al. (2014) Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. Bioimpacts 4, 83–88.
45. Asemi, Z, Samimi, M, Tabassi, Z, et al. (2013) Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial. Eur J Clin Nutr 67, 71–74.
46. Rajkumar, H, Mahmood, N, Kumar, M, et al. (2014) Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm 2014, 348959.
47. Ostadrahimi, A, Taghizadeh, A, Mobasseri, M, et al. (2015) Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health 44, 228.
48. Karamali, M, Dadkhah, F, Sadrkhanlou, M, et al. (2016) Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 42, 234–241.
49. Barreto, FM, Colado Simao, AN, Morimoto, HK, et al. (2014) Beneficial effects of Lactobacillus plantarum on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. Nutrition 30, 939–942.
50. Naruszewicz, M, Johansson, ML, Zapolska-Downar, D, et al. (2002) Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 76, 1249–1255.
51. Xiao, JZ, Kondo, S, Takahashi, N, et al. (2003) Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 86, 2452–2461.
52. Simons, LA, Amansec, SG & Conway, P (2006) Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis 16, 531–535.
53. Jones, ML, Martoni, CJ, Di Pietro, E, et al. (2012) Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul Toxicol Pharmacol 63, 313–320.
54. Yousefinejad, A, Mazloom, Z & Dabbaghmanesh, MH (2013) Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci 38, 38–43.
55. Jung, SP, Lee, KM, Kang, JH, et al. (2013) Effect of Lactobacillus gasseri BNR17 on overweight and obese adults: a randomized, double-blind clinical trial. Korean J Fam Med 34, 80–89.
56. Sharafedtinov, KK, Plotnikova, OA, Alexeeva, RI, et al. (2013) Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients – a randomized double-blind placebo-controlled pilot study. Nutr J 12, 138.
57. Gøbel, RJ, Larsen, N, Jakobsen, M, et al. (2012) Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr 55, 673–678.
58. Ogawa, A, Kadooka, Y, Kato, K, et al. (2014)
Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 13, 36.
59. Ivey, KL, Hodgson, JM, Kerr, DA, et al. (2014) The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial. Eur J Clin Nutr 68, 447–452.
60. Sanders, ME & Klaenhammer, TR (2001) Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 84, 319–331.
61. Patra, JK, Das, G, Paramithiotis, S, et al. (2016) Kimchi and other widely consumed traditional fermented foods of Korea: a review. Front Microbiol 7, 1493.
62. Kim, EK, An, SY, Lee, MS, et al. (2011) Fermented kimchi reduces body weight and improves metabolic parameters in overweight and obese patients. Nutr Res 31, 436–443.
63. An, SY, Lee, MS, Jeon, JY, et al. (2013) Beneficial effects of fresh and fermented kimchi in prediabetic individuals. Ann Nutr Metab 63, 111–119.
64. Han, K, Bose, S, Wang, JH, et al. (2015) Contrasting effects of fresh and fermented kimchi consumption on gut microbiota composition and gene expression related to metabolic syndrome in obese Korean women. Mol Nutr Food Res 59, 1004–1008.
65. Shin, GH, Kang, BC & Jang, DJ (2016) Metabolic pathways associated with kimchi, a traditional Korean food, based on in silico modeling of published data. Genomics Inform 14, 222–229.
66. Panwar, H, Rashmi, HM, Batish, VK, et al. (2013) Probiotics as potential biotherapeutics in the management of type 2 diabetes – prospects and perspectives. Diabetes Metab Res Rev 29, 103–112.
67. Belenguer, A, Duncan, SH, Calder, AG, et al. (2006) Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl Environ Microbiol 72, 3593–3599.
68. Drucker, DJ & Nauck, MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705.
69. Seeliger, S, Janssen, PH & Schink, B (2002) Energetics and kinetics of lactate fermentation to acetate and propionate via methylmalonyl-CoA or acrylyl-CoA. FEMS Microbiol Lett 211, 65–70.
70. Ma, D, Forsythe, P & Bienenstock, J (2004) Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor α-induced interleukin-8 expression. Infect Immun 72, 5308–5314.
71. Paszti-Gere, E, Szeker, K, Csibrik-Nemeth, E, et al. (2012) Metabolites of Lactobacillus plantarum 2142 prevent oxidative stress-induced overexpression of proinflammatory cytokines in IPEC-J2 cell line. Inflammation 35, 1487–1499.
72. Lambiase, A, Bracci-Laudiero, L, Bonini, S, et al. (1997) Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. J Allergy Clin Immunol 100, 408–414.
73. Ma, D, Wolvers, D, Stanisz, AM, et al. (2003) Interleukin-10 and nerve growth factor have reciprocal upregulatory effects on intestinal epithelial cells. Am J Physiol Regul Integr Comp Physiol 284, R1323–R1329.
74. Pierucci, D, Cicconi, S, Bonini, P, et al. (2001) NGF-withdrawal induces apoptosis in pancreatic β cells in vitro
. Diabetologia 44, 1281–1295.
75. Yoo, JY & Kim, SS (2016) Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients 8, 173.
76. Gibson, GR, Probert, HM, Loo, JV, et al. (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17, 259–275.
77. Flesch, AG, Poziomyck, AK & Damin, DC (2014) The therapeutic use of symbiotics. Arq Bras Cir Dig 27, 206–209.
78. Dehghan, P, Pourghassem Gargari, B & Asghari Jafar-abadi, M (2014) Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition 30, 418–423.
79. Sanz, Y & Santacruz, A (2010) Probiotics and prebiotics in metabolic disorders and obesity. In
Bioactive Foods in Promoting Health: Probiotics and Prebiotics, , pp. 237–258 [RR Watson and VR Preedy, editors]. Boston, MA: Academic Press.
80. Jackson, KG, Taylor, GR, Clohessy, AM, et al. (1999) The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. Br J Nutr 82, 23–30.
81. Russo, F, Riezzo, G, Chiloiro, M, et al. (2010) Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers. Curr Pharm Des 16, 825–831.
82. Cani, PD, Lecourt, E, Dewulf, EM, et al. (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 90, 1236–1243.
83. Brighenti, F, Casiraghi, M, Canzi, E, et al. (1999) Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. Eur J Clin Nutr 53, 726–733.
84. Letexier, D, Diraison, F & Beylot, M (2003) Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr 77, 559–564.
85. Kok, NN, Morgan, LM, Williams, CM, et al. (1998) Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats. J Nutr 128, 1099–1103.
86. Everard, A, Lazarevic, V, Derrien, M, et al. (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775–2786.
87. Yamashita, K, Kawai, K & Itakura, M (1984) Effects of fructo-oligosaccharides on blood glucose and serum lipids in diabetic subjects. Nutr Res 4, 961–966.
88. Giacco, R, Clemente, G, Luongo, D, et al. (2004) Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. Clin Nutr 23, 331–340.
89. Luo, J, Rizkalla, SW, Alamowitch, C, et al. (1996) Chronic consumption of short-chain fructooligosaccharides by healthy subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. Am J Clin Nutr 63, 939–945.
90. Parnell, JA & Reimer, RA (2009) Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89, 1751–1759.
91. Daubioul, CA, Horsmans, Y, Lambert, P, et al. (2005) Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 59, 723–726.
92. Genta, S, Cabrera, W, Habib, N, et al. (2009) Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr 28, 182–187.
93. Scheid, MM, Genaro, PS, Moreno, YM, et al. (2014) Freeze-dried powdered yacon: effects of FOS on serum glucose, lipids and intestinal transit in the elderly. Eur J Nutr 53, 1457–1464.
94. Alles, MS, de Roos, NM, Bakx, JC, et al. (1999) Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. Am J Clin Nutr 69, 64–69.
95. Luo, J, Van Yperselle, M, Rizkalla, SW, et al. (2000) Chronic consumption of short-chain fructooligosaccharides does not affect basal hepatic glucose production or insulin resistance in type 2 diabetics. J Nutr 130, 1572–1577.
96. Daud, NM, Ismail, NA, Thomas, EL, et al. (2014) The impact of oligofructose on stimulation of gut hormones, appetite regulation and adiposity. Obesity 22, 1430–1438.
97. Tovar, AR, Caamano Mdel, C, Garcia-Padilla, S, et al. (2012) The inclusion of a partial meal replacement with or without inulin to a calorie restricted diet contributes to reach recommended intakes of micronutrients and decrease plasma triglycerides: a randomized clinical trial in obese Mexican women. Nutr J 11, 44.
98. Causey, JL, Feirtag, JM, Gallaher, DD, et al. (2000) Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. Nutr Res 20, 191–201.
99. Dewulf, EM, Cani, PD, Claus, SP, et al. (2013) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62, 1112–1121.
100. Robertson, MD, Bickerton, AS, Dennis, AL, et al. (2005) Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr 82, 559–567.
101. Nilsson, AC, Johansson-Boll, EV & Bjorck, IM (2015) Increased gut hormones and insulin sensitivity index following a 3-d intervention with a barley kernel-based product: a randomised cross-over study in healthy middle-aged subjects. Br J Nutr 114, 899–907.
102. Robertson, MD, Currie, JM, Morgan, LM, et al. (2003) Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects. Diabetologia 46, 659–665.
103. Johnston, KL, Thomas, EL, Bell, JD, et al. (2010) Resistant starch improves insulin sensitivity in metabolic syndrome. Diabet Med 27, 391–397.
104. Maki, KC, Pelkman, CL, Finocchiaro, ET, et al. (2012) Resistant starch from high-amylose maize increases insulin sensitivity in overweight and obese men. J Nutr 142, 717–723.
105. Bodinham, CL, Smith, L, Thomas, EL, et al. (2014) Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr Connect 3, 75–84.
106. Behall, KM, Scholfield, DJ, Hallfrisch, JG, et al. (2006) Consumption of both resistant starch and β-glucan improves postprandial plasma glucose and insulin in women. Diabetes Care 29, 976–981.
107. Nichenametla, SN, Weidauer, LA, Wey, HE, et al. (2014) Resistant starch type 4-enriched diet lowered blood cholesterols and improved body composition in a double blind controlled cross-over intervention. Mol Nutr Food Res 58, 1365–1369.
108. Costabile, A, Klinder, A, Fava, F, et al. (2008) Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. Br J Nutr 99, 110–120.
109. Cani, PD, Possemiers, S, Van de Wiele, T, et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103.
110. Woting, A & Blaut, M (2016) The intestinal microbiota in metabolic disease. Nutrients 8, 202.
111. Dailey, MJ & Moran, TH (2013) Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 24, 85–91.
112. Verdich, C, Flint, A, Gutzwiller, JP, et al. (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86, 4382–4389.
113. De Silva, A & Bloom, SR (2012) Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 6, 10–20.
114. Meier, U & Gressner, AM (2004) Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50, 1511–1525.
115. Diamant, M, Blaak, E & De Vos, W (2011) Do nutrient–gut–microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 12, 272–281.
116. Kaji, I, Karaki, S & Kuwahara, A (2014) Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 89, 31–36.
117. Layden, BT, Angueira, AR, Brodsky, M, et al. (2013) Short chain fatty acids and their receptors: new metabolic targets. Transl Res 161, 131–140.
118. Lin, HV, Frassetto, A, Kowalik, EJ Jr, et al. (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLOS ONE 7, e35240.
119. Delzenne, NM & Cani, PD (2011) Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr 31, 15–31.
120. Cox, MA, Jackson, J, Stanton, M, et al. (2009) Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines. World J Gastroenterol 15, 5549–5557.
121. Ge, H, Li, X, Weiszmann, J, et al. (2008) Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 149, 4519–4526.
122. Zaibi, MS, Stocker, CJ, O’Dowd, J, et al. (2010) Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 584, 2381–2386.
123. Dewulf, EM, Cani, PD, Neyrinck, AM, et al. (2011) Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 22, 712–722.
124. Abrams, SA, Griffin, IJ, Hawthorne, KM, et al. (2007) Effect of prebiotic supplementation and calcium intake on body mass index. J Pediatr 151, 293–298.
125. Vinolo, MA, Rodrigues, HG, Hatanaka, E, et al. (2011) Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 22, 849–855.
126. Tedelind, S, Westberg, F, Kjerrulf, M, et al. (2007) Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 13, 2826–2832.
127. Liu, T, Li, J, Liu, Y, et al. (2012) Short-chain fatty acids suppress lipopolysaccharide-induced production of nitric oxide and proinflammatory cytokines through inhibition of NF-κB pathway in RAW264.7 cells. Inflammation 35, 1676–1684.
128. Park, JS, Lee, EJ, Lee, JC, et al. (2007) Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells: involvement of NF-κB and ERK signaling pathways. Int Immunopharmacol 7, 70–77.
129. De Caterina, R, Libby, P, Peng, HB, et al. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96, 60–68.
130. Moncada, S & Higgs, A (1993) The l-arginine–nitric oxide pathway. N Engl J Med 329, 2002–2012.
131. Murohara, T, Asahara, T, Silver, M, et al. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101, 2567–2578.
132. Rudic, RD, Shesely, EG, Maeda, N, et al. (1998) Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101, 731–736.
133. Sharma, JN, Al-Omran, A & Parvathy, SS (2007) Role of nitric oxide in inflammatory diseases. Inflammopharmacology 15, 252–259.
134. Usami, M, Kishimoto, K, Ohata, A, et al. (2008) Butyrate and trichostatin A attenuate nuclear factor κB activation and tumor necrosis factor α secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res 28, 321–328.
135. Park, GY, Joo, M, Pedchenko, T, et al. (2004) Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am J Physiol Lung Cell Mol Physiol 286, L956–L962.
136. Zapolska-Downar, D, Siennicka, A, Kaczmarczyk, M, et al. (2004) Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-κB and PPARα. J Nutr Biochem 15, 220–228.
137. Menzel, T, Luhrs, H, Zirlik, S, et al. (2004) Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm Bowel Dis 10, 122–128.
138. Zapolska-Downar, D & Naruszewicz, M (2009) Propionate reduces the cytokine-induced VCAM-1 and ICAM-1 expression by inhibiting nuclear factor-κB (NF-κB) activation. J Physiol Pharmacol 60, 123–131.
139. Bohmig, GA, Krieger, PM, Saemann, MD, et al. (1997)
n-Butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology 92, 234–243.
140. Alex, S, Lichtenstein, L, Dijk, W, et al. (2014) ANGPTL4 is produced by entero-endocrine cells in the human intestinal tract. Histochem Cell Biol 141, 383–391.
141. Köster, A, Chao, YB, Mosior, M, et al. (2005) Transgenic angiopoietin-like (Angptl)4 overexpression and targeted disruption of Angptl4 and Angptl3: regulation of triglyceride metabolism. Endocrinology 146, 4943–4950.
142. Dewey, FE, Gusarova, V, O’Dushlaine, C, et al. (2016) Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med 374, 1123–1133.
143. Xu, A, Lam, MC, Chan, KW, et al. (2005) Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A 102, 6086–6091.
144. Lichtenstein, L, Mattijssen, F, de Wit, NJ, et al. (2010) Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab 12, 580–592.
145. Georgiadi, A, Lichtenstein, L, Degenhardt, T, et al. (2010) Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor β/δ and protects against fatty acid-induced oxidative stress. Circ Res 106, 1712–1721.
146. Demigné, C, Morand, C, Levrat, M-A, et al. (1995) Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br J Nutr 74, 209–219.
147. Grootaert, C, Van de Wiele, T, Van Roosbroeck, I, et al. (2011) Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ Microbiol 13, 1778–1789.
148. Ferré, P (2004) The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 53, S43–S50.
149. Bouskila, M, Pajvani, U & Scherer, P (2005) Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes 29, S17–S23.
150. Rutter, GA, Da Silva Xavier, G & Leclerc, I (2003) Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 375, 1–16.
151. Korecka, A, De Wouters, T, Cultrone, A, et al. (2013) ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways. Am J Physiol Gastrointest Liver Physiol 304, G1025–G1037.
152. De Vadder, F, Kovatcheva-Datchary, P, Goncalves, D, et al. (2014) Microbiota-generated metabolites promote metabolic benefits via gut–brain neural circuits. Cell 156, 84–96.
153. Troy, S, Soty, M, Ribeiro, L, et al. (2008) Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 8, 201–211.
154. Mithieux, G, Misery, P, Magnan, C, et al. (2005) Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab 2, 321–329.
155. Gautier-Stein, A, Zitoun, C, Lalli, E, et al. (2006) Transcriptional regulation of the glucose-6-phosphatase gene by cAMP/vasoactive intestinal peptide in the intestine. Role of HNF4α, CREM, HNF1α, and C/EBPα. J Biol Chem 281, 31268–31278.
156. DeFronzo, R (1992) Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35, 389–397.
157. Magnusson, I, Rothman, D, Katz, L, et al. (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90, 1323.
158. Mithieux, G (2014) Nutrient control of energy homeostasis via gut–brain neural circuits. Neuroendocrinology 100, 89–94.
159. Nazzaro, F, Fratianni, F, Nicolaus, B, et al. (2012) The prebiotic source influences the growth, biochemical features and survival under simulated gastrointestinal conditions of the probiotic Lactobacillus acidophilus
. Anaerobe 18, 280–285.
160. Moroti, C, Souza Magri, LF, de Rezende Costa, M, et al. (2012) Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 11, 29.
161. Asemi, Z, Zare, Z, Shakeri, H, et al. (2013) Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 63, 1–9.
162. Rajkumar, H, Kumar, M, Das, N, et al. (2015) Effect of probiotic Lactobacillus salivarius UBL S22 and prebiotic fructo-oligosaccharide on serum lipids, inflammatory markers, insulin sensitivity, and gut bacteria in healthy young volunteers: a randomized controlled single-blind pilot study. J Cardiovasc Pharmacol Ther 20, 289–298.
163. Eslamparast, T, Zamani, F, Hekmatdoost, A, et al. (2014) Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br J Nutr 112, 438–445.
164. Tajadadi-Ebrahimi, M, Bahmani, F, Shakeri, H, et al. (2014) Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial. Ann Nutr Metab 65, 34–41.
165. Asemi, Z, Khorrami-Rad, A, Alizadeh, SA, et al. (2014) Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33, 198–203.
166. Taghizadeh, M & Asemi, Z (2014) Effects of synbiotic food consumption on glycemic status and serum hs-CRP in pregnant women: a randomized controlled clinical trial. Hormones (Athens) 13, 398–406.
167. Wong, VW, Won, GL, Chim, AM, et al. (2013) Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 12, 256–262.
168. Eslamparast, T, Poustchi, H, Zamani, F, et al. (2014) Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99, 535–542.
169. Mofidi, F, Poustchi, H, Yari, Z, et al. (2017) Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr 117, 662–668.
170. Bahmani, F, Tajadadi-Ebrahimi, M, Kolahdooz, F, et al. (2016) The consumption of synbiotic bread containing Lactobacillus sporogenes and inulin affects nitric oxide and malondialdehyde in patients with type 2 diabetes mellitus: randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 35, 506–513.
171. Shakeri, H, Hadaegh, H, Abedi, F, et al. (2014) Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids 49, 695–701.